Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma

Christina K. Augustine, Sin-Ho Jung, Insuk Sohn, Jin Soo Yoo, Yasunori Yoshimoto, John A. Olson, Jr., Henry S. Friedman, Francis Ali-Osman, Douglas S. Tyler

Mol Cancer Ther (2010) 9 (4): 779–790.

DOI: https://doi.org/10.1158/1535-7163.MCT-09-0764

Published: 07 April 2010

View article

Includes: Supplementary data

Journal Articles

Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

Peter J. Houghton, John M. Maris, Josh Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, E. Anders Kolb, Richard Gorlick, Min Kang, C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith

Mol Cancer Ther (2009) 8 (12_Supplement): C57.

DOI: https://doi.org/10.1158/1535-7163.TARG-09-C57

Published: 10 December 2009

View article

Journal Articles

An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

John H. Sampson, Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, James E. Herndon, II, Denise Lally-Goss, Sharon McGehee-Norman, Alison Paolino, David A. Reardon, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner

Mol Cancer Ther (2009) 8 (10): 2773–2779.

DOI: https://doi.org/10.1158/1535-7163.MCT-09-0124

Published: 12 October 2009

View article

Journal Articles

The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion

Anita B. Hjelmeland, Kathryn P. Lattimore, Brian E. Fee, Qing Shi, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, David Batt, Darell D. Bigner, Henry S. Friedman, Jeremy N. Rich

Mol Cancer Ther (2007) 6 (9): 2449–2457.

DOI: https://doi.org/10.1158/1535-7163.MCT-07-0155

Published: 17 September 2007

View article

Journal Articles

Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents

Yasunori Yoshimoto, Christina K. Augustine, Jin S. Yoo, Patricia A. Zipfel, M. Angelica Selim, Scott K. Pruitt, Henry S. Friedman, Francis Ali-Osman, Douglas S. Tyler

Mol Cancer Ther (2007) 6 (5): 1492–1500.

DOI: https://doi.org/10.1158/1535-7163.MCT-06-0718

Published: 18 May 2007

View article

Journal Articles

Quantitative analysis of O⁶-alkylguanine-DNA alkyltransferase in malignant glioma

Jill A. Maxwell, Stewart P. Johnson, Jennifer A. Quinn, Roger E. McLendon, Francis Ali-Osman, Allan H. Friedman, James E. Herndon, II, Katja Bierau, Joseph Bigley, Darell D. Bigner, Henry S. Friedman

Mol Cancer Ther (2006) 5 (10): 2531–2539.

DOI: https://doi.org/10.1158/1535-7163.MCT-06-0106

Published: 13 October 2006

View article

Journal Articles

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O⁶-benzylguanine

Tomio Ueno, Sae Hee Ko, Elizabeth Grubbs, Yasunori Yoshimoto, Christi Augustine, Zeinab Abdel-Wahab, Tsung-Yen Cheng, Omar I. Abdel-Wahab, Scott K. Pruitt, Henry S. Friedman, Douglas S. Tyler

Mol Cancer Ther (2006) 5 (3): 732–738.

DOI: https://doi.org/10.1158/1535-7163.MCT-05-0098

Published: 16 March 2006

View article

Journal Articles

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft

C. Lynn Cheng, Stewart P. Johnson, Stephen T. Keir, Jennifer A. Quinn, Francis Ali-Osman, Csaba Szabo, Hongshan Li, Andrew L. Salzman, M. Eileen Dolan, Paul Modrich, Darell D. Bigner, Henry S. Friedman

Mol Cancer Ther (2005) 4 (9): 1364–1368.

DOI: https://doi.org/10.1158/1535-7163.MCT-05-0128

Published: 16 September 2005

View article

Journal Articles

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Ranjit K. Goudar, Qing Shi, Mark D. Hjelmeland, Stephen T. Keir, Roger E. McLendon, Carol J. Wikstrand, Elizabeth D. Reese, Charles A. Conrad, Peter Traxler, Heidi A. Lane, David A. Reardon, Webster K. Cavenee, Xiao-Fan Wang, Darell D. Bigner, Henry S. Friedman, Jeremy N. Rich

Mol Cancer Ther (2005) 4 (1): 101–112.

DOI: https://doi.org/10.1158/1535-7163.101.4.1

Published: 18 January 2005

View article

Journal Articles

Brain tumor cell lines resistant to O⁶-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O⁶-alkylguanine-DNA alkyltransferase mutations

Manny D. Bacolod, Stewart P. Johnson, Anthony E. Pegg, M. Eileen Dolan, Robert C. Moschel, Nancy S. Bullock, Qingming Fang, O. Michael Colvin, Paul Modrich, Darell D. Bigner, Henry S. Friedman

Mol Cancer Ther (2004) 3 (9): 1127–1135.

DOI: https://doi.org/10.1158/1535-7163.1127.3.9

Published: 14 September 2004

View article

Journal Articles

SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility

Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee, Elizabeth D. Reese, Michael H. Herbstreith, Nicholas J. Laping, Henry S. Friedman, Darell D. Bigner, Xiao-Fan Wang, Jeremy N. Rich

Mol Cancer Ther (2004) 3 (6): 737–745.

DOI: https://doi.org/10.1158/1535-7163.737.3.6

Published: 21 June 2004

View article

Journal Articles

O⁶-Benzylguanine-mediated Enhancement of Chemotherapy

Henry S. Friedman, Stephen Keir, Anthony E. Pegg, Peter J. Houghton, O. Michael Colvin, Robert C. Moschel, Darell D. Bigner, M. Eileen Dolan

Mol Cancer Ther (2002) 1 (11): 943–948.

Published: 01 September 2002

View article

Journal Articles

Mechanisms of Resistance to 1,3-Bis(2-chloroethyl)-1-nitrosourea in Human Medulloblastoma and Rhabdomyosarcoma

Manny D. Bacolod, Stewart P. Johnson, Francis Ali-Osman, Paul Modrich, Nancy S. Bullock, O. Michael Colvin, Darell D. Bigner, Henry S. Friedman

Mol Cancer Ther (2002) 1 (9): 727–736.

Published: 01 July 2002

View article

NARROW

Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma

Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion

Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents

Quantitative analysis of O⁶-alkylguanine-DNA alkyltransferase in malignant glioma

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O⁶-benzylguanine

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Brain tumor cell lines resistant to O⁶-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O⁶-alkylguanine-DNA alkyltransferase mutations

SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility

O⁶-Benzylguanine-mediated Enhancement of Chemotherapy

Mechanisms of Resistance to 1,3-Bis(2-chloroethyl)-1-nitrosourea in Human Medulloblastoma and Rhabdomyosarcoma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only